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Abstract
Adaptor proteins, with multi-modular structures, can participate in the regulation of various cellular functions. During
molecular cloning process of actin filament associated protein, we have discovered a novel adaptor protein, referred
to as XB130. The human xb130 gene is localized on chromosome 10q25.3, and encodes an 818 amino acid protein.
The N-terminal region of XB130 includes several tyrosine phosphorylation sites and a proline-rich sequence that
might interact with Src homology 2 and 3 domain-containing proteins, respectively. Our studies have indeed
implicated XB130 as a likely substrate and regulator of tyrosine kinase-mediated signaling. Down-regulation of
endogenous XB130 with small interfering RNA reduced c-Src activity, IL-8 production and phosphorylation of Akt in
human lung epithelial cells. Further, XB130 binds the p85a subunit of phosphatidyl-inositol-3-kinase and
subsequently mediates signaling through RET/PTC in thyroid cancer cells. Knockdown of XB130 using small
interfering RNA inhibited G1-S phase progression, induced spontaneous apoptosis and enhanced intrinsic and
extrinsic apoptotic stimulus-induced cell death in human lung and thyroid cancer cells. Growth of tumors in nude
mice formed from XB130 short hairpin RNA stably transfected human thyroid cancer cells were significantly reduced,
with decreased cell proliferation and increased apoptosis. Further, XB130 has a high affinity to lamellipodial F-actin
meshwork and is involved in the motility and invasiveness of cancer cells. Gene expression profiling identified 246
genes significantly changed in XB130 short hairpin RNA transfected thyroid cancer cells. Among them, 57 genes are
related to cell proliferation or survival, including many transcription regulators. Pathway analysis showed that the top
ranked disease related to XB130 is Cancer, and the top molecular and cellular functions are Cellular Growth and
Proliferation, and Cell Cycle. These observations suggest that the expression of XB130 may affect cell proliferation,
survival, motility and invasion in various cancer cells. A deeper understanding of these mechanisms may lead to the
discovery of XB130 as an important mediator in tumor development and as a novel therapeutic target for cancer.
Review
Introduction
Adaptor proteins are molecules of modular structures
without enzymatic activity, composed of multiple
protein-protein and/or protein-lipid interacting domains,
through which they link signaling components to form
macromolecular complexes and propagate cellular signals
[1,2]. Depending on the functional role of the interacting
partner and the specific biological event that is triggered
by these interactions, adaptor proteins can participate in
the regulation of different signaling pathways. A good
example of how adaptor proteins are involved in signal
transduction is the activation of c-Src protein-tyrosine
kinases by adaptor proteins via protein-protein interac-
tions. Adaptor proteins are also important to mediate
signals initiated via receptor-tyrosine kinases in responses
to extracellular stimuli [3,4], and together with non-
receptor protein-tyrosine kinases to orchestrate the signal
transduction elicited by either ligand receptor interac-
tions or by cellular structure reorganization [5]. Further,
a number of adaptor proteins have been demonstrated to
regulate tumorigenesis. For example, actin filament asso-
ciated protein (AFAP) is required for actin stress fiber
formation and cell adhesion, and is critical for tumori-
genic growth in prostate cancer [6,7]. Tyrosine kinase
substrate 5 is a scaffolding adaptor protein with five Src
homology (SH) 3 domains, co-localizes to podosomes
and regulates migration and invasion of different human
cancer cells [8,9]. These findings support a broader inves-
tigation of adaptor proteins on tumorigenesis and their
potentiality as diagnostic biomarkers and therapeutic tar-
gets of cancer.
During our studies aimed at the characterization of
the AFAP [10-12], we cloned a novel 130 kDa protein,
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cated that XB130 plays, as an adaptor, important roles
in the regulation of signal transduction, cell prolifera-
tion, survival, motility and invasion [13-16]. In this
review, we focus on studies relate to both XB130 and
cancer progression.
Molecular structure of XB130
The human xb130 gene is localized on chromosome
10q25.3 and encodes 818 amino acids with an apparent
molecular size of approximately 130 kDa [13]. As an
adaptor protein, the overall structure of XB130 shares
similarity with AFAP, thus it is also known as actin fila-
ment associated protein 1-like 2 (AFAP1L2). The
N-terminal region of XB130 includes several tyrosine
phosphorylation sites and a proline-rich sequence which
can potentially interact with SH2 and SH3 domain-
containing proteins, respectively (Figure 1) [13,14]. The
middle portion harbors two pleckstrin-homology (PH)
domains that may target proteins to cellular membranes
through interactions with specific phospholipids, such
as phosphoatidylinositol-3, 4, 5-triphosphate. The
C-terminal region contains a coiled-coil domain, which
might be involved in protein oligomerization and DNA
binding. A common feature of XB130 and AFAP is the
presence of a proline-rich motif, several potential SH2-
binding sites and two PH domains (Figure 1) [13,14].
A coiled-coil domain of XB130 shares partial similarity
with the leucine zipper domain in AFAP. Despite these
similarities, XB130 does not behave like an actin fila-
ment-associated protein. The actin-binding site that is
present in the C terminus of AFAP [17] is only partially
present in XB130. The distribution of AFAP appears to
be along the stress fiber, and through its interaction,
AFAP transmits physical force and mediates mechanical
stretch-induced c-Src activation [12,18]. On the other
hand, the diffuse distribution of XB130 in the cytoplasm
suggests that XB130 plays a different role in signal
transduction and cellular functions [13]. XB130’s tissue
distribution was determined by using northern blot ana-
lysis and high expression of XB130 was found in human
thyroid and spleen [14].
Regulation of tyrosine kinase-mediated signaling by
XB130
Our studies have implicated XB130 as a likely substrate
and regulator of tyrosine kinase-mediated signaling
[13,14]. Endogenous XB130 interacts with c-Src tyrosine
kinase [13]. Their co-expression in COS-7 cells resulted
in activation of c-Src and elevated tyrosine phosphoryla-
tion of multiple proteins, including XB130 itself. XB130
expression in HEK293 cells enhanced serum response
element- and AP-1-dependent transcriptional activation
mediated by c-Src. Down-regulation of endogenous
XB130 with small interfering RNA (siRNA) reduced c-
Src activity, IL-8 production, epidermal growth factor
(EGF)-induced phosphorylation of Akt and GSK3b in
human lung cancer A549 cells [13].
Further, our studies revealed expression of XB130 in
human thyroid tissue, and we found that XB130 is a
downstream mediator of the signaling cascade propa-
gated by RET/PTC, a genetically rearranged, constitu-
tively active, thyroid cancer-specific tyrosine kinase [14].
RET/PTC plays a pathogenic role and exhibits transform-
ing ability by exerting its effects on differentiation,
mitogenic and metastatic potential in papillary thyroid
cancer [19,20]. XB130 couples RET/PTC signaling to the
phosphatidyl-inositol-3-kinase (PI3K)/Akt signaling
through a specific binding site to p85a subunit of PI3K
[14]. A study investigating the implications of Src
PH1 PH2 C-C XB130
SH3 binding motif
SH2 binding motif
PH1 PH2 LZ AFAP
PH: pleckstrin homology domain
C-C: coiled-coil domain
LZ: leucine zipper domain
AB: actin binding domein
AB
Figure 1 Schematic representation of the XB130 and AFAP protein structures. The N-terminal region of XB130 includes several tyrosine
phosphorylation sites and a proline-rich sequence that may interact with Src homology (SH) 2 and SH3 domain-containing proteins. The middle
portion harbors two pleckstrin homology (PH) domains, while the C-terminal region contains a coiled-coil domain. A common feature of XB130
(818aa) and AFAP (730aa) is the presence of potential SH2, SH3-binding sites and two PH domains. A coiled-coil domain of XB130 shares partial
similarity with the leucine zipper domain and in AFAP.
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din et al. identified XB130 from SW629 colorectal cancer
cells, as one of the tyrosine phosphorylated proteins
binding to Lck-SH2 domain [21]. Lck, is a Src family
member that is not detectable in normal colonic epithe-
lium, but becomes aberrantly expressed in a subset of
colorectal carcinomas. These findings indicate that
XB130 has an important role in the regulation of tyrosine
kinase-mediated signaling.
Roles of XB130 in cell cycle and survival
To investigate the role of XB130 in cancer cell cycle pro-
gression, we conducted knockdown experiments with
XB130 siRNA [13-15]. Down regulation of XB130 reduced
cell cycle progression from G1 to S phase in human lung
cancer cell line, A549 and human thyroid cancer cell lines,
TPC1 and WRO (Figure 2) [13-15]. The expression of cell
proliferation markers, Ki-67 and PCNA, were also reduced
in XB130 siRNA treated WRO cells [15]. Down-regulation
of XB130 induced apoptosis and enhanced extrinsic or
intrinsic apoptotic stimulus-induced early and late apopto-
sis in WRO cells (Figure 2) [15]. In TPC1 cells, down-reg-
ulation of XB130 accelerates the apoptotic process [14].
Further, to determine the roles of XB130 in vivo, we estab-
lished XB130 short hairpin RNA (shRNA) stably trans-
fected WRO cell lines and used a xenograft model in nude
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Figure 2 Roles of XB130 in cell cycle and survival of cancer. XB130 specifically binds p85a subunit of PI3K, which subsequently activate Akt.
Akt plays an essential role in cell proliferation and survival.
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XB130 shRNA stably transfected WRO cells were signifi-
cantly reduced, with decreased cell proliferation and
increased apoptosis. These findings indicate that XB130
expression levels affected cell proliferation and survival in
cancer cells (Figure 2).
Roles of XB130 in cell motility and invasion
We further found that XB130 has a high affinity to lamelli-
podial F-actin meshwork and is involved in the motility
and invasiveness of tumor cells. XB130 exhibited robust
translocation to the cell periphery in response to various
stimuli (including EGF, wounding and expression of consti-
tutively active Rac) that elicit lamellipodium formation [16].
Structure-function analysis revealed that both the XB130
N-terminus and C-terminus harbor critical regions for its
translocation to lamellipodia [16]. In TPC1 thyroid papil-
lary carcinoma cells, silencing endogenous XB130
decreased the rate of wound closure, inhibited cell invasion
through Matrigel, reduced lamellipodial persistence and
slowed down spreading [16]. Thus, XB130 is a novel Rac/
cytoskeleton-regulated and cytoskeleton-regulating adaptor
protein, which exhibits high affinity to lamellipodial F-actin
and impacts motility and invasiveness of tumor cells.
Gene expression profile in XB130 shRNA transfected cells
To determine the molecular mechanisms by which
XB130 regulates cellular functions, we analyzed gene
expression profiles in XB130 shRNA transfected cells by
microarray and bioinformatics studies [15]. Microarray
analysis identified 246 genes significantly changed in
XB130 shRNA transfected cells. Among them, 57 genes,
such as HSPA1A, BHLHE40,T O B 1 ,D D I T 3 ,S L C 7 A 1 1
and MYC are related to cell proliferation or survival,
including many transcription regulators. Ingenuity Path-
way Analysis showed that the top ranked disease related
to XB130 is Cancer, and the top molecular and cellular
functions are Cellular Growth and Proliferation, and
Cell Cycle [15]. These results indicate that the expres-
sion level of XB130 influences genes related to cellular
growth and proliferation, cell cycle, cell death and orga-
nismal survival. Furthermore, Cunha et al. performed
gene expression profiling using 102 soft tissue tumor
samples, and found XB130 as one of the genes highly
related to local aggressiveness [22]. Therefore, in addi-
tion to thyroid cancer, XB130 may also play important
roles in other neoplasms.
Conclusions
We have provided evidence that XB130 plays important
roles in tumor progression by promoting cell prolifera-
tion, survival, motility and invasion in various cancer
cells (Figure 3). XB130 has profound effects on expres-
sion of genes related to tumorigenesis. These findings
suggest that XB130 could be a novel oncoprotein in
cancer. A deeper understanding of these mechanisms
Binding Partner
pY
pY XB130
pY
pY XB130 Binding Partner
inactive
active
tyrosine kinase-mediated signaling
Cell cycle
Survival
Migration
Invasion
transcriptional activation
PI3K
Src
Figure 3 Roles of XB130 in cancer behavior. XB130 interacts with binding partners and regulates cell cycle, survival, migration and invasion of
cancer through tyrosine kinase-mediated signaling.
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Page 4 of 5may lead to the discovery of XB130 as an important
mediator in tumor development and as a novel thera-
peutic target for cancer.
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